Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763627 | 0.84 | MEN1 (0.44) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL2786159 | 0.80 | ALDH1A1 (0.54) | MEN1KMT2AHPGDALDH1A1BRD4 | |
| SCHEMBL4164688 | 0.80 | ALDH1A1 (0.51) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL1584775 | 0.80 | ALDH1A1 (0.51) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL7521745 | 0.80 | ALDH1A1 (0.48) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL27422649 | 0.80 | ALDH1A1 (0.49) | KMT2AHPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL11315740 | 0.79 | HPGD (0.50) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL15978138 | 0.79 | FPR1 (0.51) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| Hydrogen Sulfide SCHEMBL27583639 | 0.79 | HPGD (0.50) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL3993882 | 0.76 | KDM4E (0.48) | HPGDALDH1A1KDM4ESMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203910-A1 | Deprotection of N-BOC compounds | ROCH PALO ALTO LLC | 2009-08-13 | — | — | US | disclosed |
| EP-2070899-A1 | Deprotection of N-BOC compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-5869666-A | Conformationally locked nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-02-09 | — | — | US | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203910-A1 | Deprotection of N-BOC compounds | NUCB2, TERT, CEL | MEN1 425/4885KMT2A 2901/4885HPGD 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.